Annovis Bio is a Phase 3 clinical-stage biotechnology company focused on chronic and acute neurodegenerative diseases.
The company is advancing a pivotal Phase 3 clinical trial in early Alzheimer’s disease toward a top-line data readout.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The company’s lead investigational oral therapy, buntanetap, is designed to inhibit overproduction of multiple neurotoxic proteins through an RNA-targeted translational mechanism.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
Open the published source list.RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 3, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 19, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.